BACKGROUND: In young adults with acute myeloid leukemia (AML), intensification of the anthracycline dose during induction therapy has improved the rate of complete remission but not of overall survival. We evaluated the use of cytarabine plus either standard-dose or high-dose daunorubicin as induction therapy, followed by intensive consolidation therapy, in inducing complete remission to improve overall survival. METHODS: In this phase 3 randomized trial, we assigned 657 patients between the ages of 17 and 60 years who had untreated AML to receive three once-daily doses ofdaunorubicin at either the standard dose (45 mg per square meter of body-surface area) or a high dose (90 mg per square meter), combined with seven daily doses of cytarabine (100 mg per square meter) by continuous intravenous infusion. Patients who had a complete remission were offered either allogeneic hematopoietic stem-cell transplantation or high-dose cytarabine, with or without a single dose of the monoclonal antibody gemtuzumab ozogamicin, followed by autologous stem-cell transplantation. The primary end point was overall survival. RESULTS: In the intention-to-treat analysis, high-dose daunorubicin, as compared with a standard dose of the drug, resulted in a higher rate of complete remission (70.6% vs. 57.3%, P<0.001) and improved overall survival (median, 23.7 vs. 15.7 months; P=0.003). The rates of serious adverse events were similar in the two groups. Median follow-up was 25.2 months. CONCLUSIONS: In young adults with AML, intensifying induction therapy with a high daily dose of daunorubicin improved the rate of complete remission and the duration of overall survival, as compared with the standard dose. (ClinicalTrials.gov number, NCT00049517.) 2009 Massachusetts Medical Society
RCT Entities:
BACKGROUND: In young adults with acute myeloid leukemia (AML), intensification of the anthracycline dose during induction therapy has improved the rate of complete remission but not of overall survival. We evaluated the use of cytarabine plus either standard-dose or high-dose daunorubicin as induction therapy, followed by intensive consolidation therapy, in inducing complete remission to improve overall survival. METHODS: In this phase 3 randomized trial, we assigned 657 patients between the ages of 17 and 60 years who had untreated AML to receive three once-daily doses of daunorubicin at either the standard dose (45 mg per square meter of body-surface area) or a high dose (90 mg per square meter), combined with seven daily doses of cytarabine (100 mg per square meter) by continuous intravenous infusion. Patients who had a complete remission were offered either allogeneic hematopoietic stem-cell transplantation or high-dose cytarabine, with or without a single dose of the monoclonal antibody gemtuzumab ozogamicin, followed by autologous stem-cell transplantation. The primary end point was overall survival. RESULTS: In the intention-to-treat analysis, high-dose daunorubicin, as compared with a standard dose of the drug, resulted in a higher rate of complete remission (70.6% vs. 57.3%, P<0.001) and improved overall survival (median, 23.7 vs. 15.7 months; P=0.003). The rates of serious adverse events were similar in the two groups. Median follow-up was 25.2 months. CONCLUSIONS: In young adults with AML, intensifying induction therapy with a high daily dose of daunorubicin improved the rate of complete remission and the duration of overall survival, as compared with the standard dose. (ClinicalTrials.gov number, NCT00049517.) 2009 Massachusetts Medical Society
Authors: J K Weick; K J Kopecky; F R Appelbaum; D R Head; L L Kingsbury; S P Balcerzak; J N Bickers; H E Hynes; J L Welborn; S R Simon; M Grever Journal: Blood Date: 1996-10-15 Impact factor: 22.113
Authors: Z Arlin; D C Case; J Moore; P Wiernik; E Feldman; S Saletan; P Desai; L Sia; K Cartwright Journal: Leukemia Date: 1990-03 Impact factor: 11.528
Authors: J M Bennett; M L Young; J W Andersen; P A Cassileth; M S Tallman; E Paietta; P H Wiernik; J M Rowe Journal: Cancer Date: 1997-12-01 Impact factor: 6.860
Authors: J J van Dongen; E A Macintyre; J A Gabert; E Delabesse; V Rossi; G Saglio; E Gottardi; A Rambaldi; G Dotti; F Griesinger; A Parreira; P Gameiro; M G Diáz; M Malec; A W Langerak; J F San Miguel; A Biondi Journal: Leukemia Date: 1999-12 Impact factor: 11.528
Authors: J Yates; O Glidewell; P Wiernik; M R Cooper; D Steinberg; H Dosik; R Levy; C Hoagland; P Henry; A Gottlieb; C Cornell; J Berenberg; J L Hutchison; P Raich; N Nissen; R R Ellison; R Frelick; G W James; G Falkson; R T Silver; F Haurani; M Green; E Henderson; L Leone; J F Holland Journal: Blood Date: 1982-08 Impact factor: 22.113
Authors: H Preisler; R B Davis; J Kirshner; E Dupre; F Richards; H C Hoagland; S Kopel; R N Levy; R Carey; P Schulman Journal: Blood Date: 1987-05 Impact factor: 22.113
Authors: P H Wiernik; P L Banks; D C Case; Z A Arlin; P O Periman; M B Todd; P S Ritch; R E Enck; A B Weitberg Journal: Blood Date: 1992-01-15 Impact factor: 22.113
Authors: J M Rowe; J W Andersen; J J Mazza; J M Bennett; E Paietta; F A Hayes; D Oette; P A Cassileth; E A Stadtmauer; P H Wiernik Journal: Blood Date: 1995-07-15 Impact factor: 22.113
Authors: R J Mayer; R B Davis; C A Schiffer; D T Berg; B L Powell; P Schulman; G A Omura; J O Moore; O R McIntyre; E Frei Journal: N Engl J Med Date: 1994-10-06 Impact factor: 91.245
Authors: Edward Agura; Barry Cooper; Houston Holmes; Estil Vance; Robert Brian Berryman; Christopher Maisel; Sandy Li; Giovanna Saracino; Mirjana Tadic-Ovcina; Joseph Fay Journal: Oncologist Date: 2011-01-27
Authors: Kelly J Norsworthy; Amy E DeZern; Hua-Ling Tsai; Wesley A Hand; Ravi Varadhan; Steven D Gore; Ivana Gojo; Keith Pratz; Hetty E Carraway; Margaret Showel; Michael A McDevitt; Douglas Gladstone; Gabriel Ghiaur; Gabrielle Prince; Amy H Seung; Dina Benani; Mark J Levis; Judith E Karp; B Douglas Smith Journal: Leuk Res Date: 2017-08-30 Impact factor: 3.156
Authors: Chezi Ganzel; Judith Manola; Dan Douer; Jacob M Rowe; Hugo F Fernandez; Elisabeth M Paietta; Mark R Litzow; Ju-Whei Lee; Selina M Luger; Hillard M Lazarus; Larry D Cripe; Peter H Wiernik; Martin S Tallman Journal: J Clin Oncol Date: 2016-10-10 Impact factor: 44.544